HCV Archives – Page 7 of 29 – Treatment Action Group

Civil Society Letter to Cepheid Requesting Lower Prices for Xpert SARS-CoV-2 Tests and Increased Volumes Distributed to LMICs

February 25, 2021
Dorrit Walsh

February 25, 2021 — TAG signed onto this letter requesting that diagnostics company Cepheid increase access to Xpert SARS-CoV-2 tests in low- and middle-income countries (LMICs) by committing a greater proportion of its SARS-CoV-2 test manufacturing capacity to LMICs and…

Harnessing the COVID-19 Response Towards Hepatitis C Elimination

February 3, 2021
Dorrit Walsh

On February 3, 2021, TAG, Médecins du Monde, hepCoalition, and the UNITE network presented a virtual policy dialogue among policymakers, global civil society organizations, and community leaders who share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

Harnessing the COVID-19 Response Towards Hepatitis C Elimination

February 1, 2021
Dorrit Walsh

On Wednesday, February 3, 2021, Treatment Action Group, Médecins du Monde, hepCoalition, and the UNITE network convene a virtual policy dialogue among parliamentarians, global civil society organizations, and community leaders to share how COVID-19 has impacted global hepatitis C virus (HCV) elimination efforts.

Cover of the brief: Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

Hepatitis C and COVID-19 Global Concerns: Sustained Financing and Expanded Access to Testing and Pangenotypic Treatments Needed to Recover the Path to Elimination

February 1, 2021
Dorrit Walsh

This policy brief highlights strategies that leverage the COVID-19 response towards improving access to HCV diagnostics, treatment, and care.

2020 TAG Update

December 11, 2020
Dorrit Walsh

As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

TAGline November 2020

November 11, 2020
Dorrit Walsh

'The Struggle of a Lifetime' (Continued): The words of the late Honorable John Lewis ring powerfully true today. In the U.S., as we welcome a new President-elect and Vice President-elect, we must also defend democracy to ensure a complete, peaceful transition of power. We engage in the struggles generations before us have advanced, despite myriad challenges and emerging new threats such as COVID-19.

Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement

November 9, 2020
Dorrit Walsh

Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.

TAG Welcomes the Election of Joseph R. Biden Jr. and Kamala D. Harris

November 9, 2020
Dorrit Walsh

Treatment Action Group (TAG) congratulates President-elect Joe Biden and Vice President-elect Kamala Harris on their ascension to the highest offices of the United States. Their victory in both the popular and electoral vote is historic.

Research in Action Awards 2020

October 1, 2020
Dorrit Walsh

Please join us at our annual, and first ever virtual, Research in Action Awards on Thursday, November 19, 2020. At this time of great turmoil and when activism to end infectious disease is more vital than ever, it’s so important to gather virtually to celebrate life, commemorate those we’ve lost, and recognize champions of progress and justice.

New York Increases Access to Hepatitis C Treatment for Medicaid Patients

September 21, 2020
Dorrit Walsh

The National Viral Hepatitis Roundtable (NVHR), the Center for Health Law and Policy Innovation of Harvard Law School (CHLPI), and the Treatment Action Group (TAG) today applauded New York State (NYS) Medicaid for removing the requirement that new patients receive prior authorization approval for hepatitis C treatment.